An RNA Revolution in Lowering LDL Cholesterol: Leqvio-Lyptimzia with Inclisiran
In this article
A precise solution that calms the silent storm in our arteries: Inclisiran (Leqvio/Lyptimzia): a technical analysis and guide.
Mechanism of action: Stopping protein production at its source with siRNA
Leqvio/Lyptimzia (inclisiran) is based on “small interfering RNA” (siRNA) technology. While conventional drugs target proteins already present in the body, inclisiran directly silences the intracellular “production line” .
Entering liver cells (hepatocytes) with the help of a special sugar molecule (GalNAc), inclisiran breaks down the mRNA encoding the PCSK9 protein, stopping synthesis at its source.
When PCSK9 protein levels in the blood decrease, LDL receptors on the liver surface survive without being degraded and clear “bad cholesterol” from the blood much more effectively.
The architecture of clinical success: Design of the ORION trials
FDA approval was built on comprehensive phase III trials (ORION-9, -10 and -11) involving a total of 3457 patients. These studies targeted patients with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolaemia (HeFH) whose LDL-C remained high despite maximally dosed statins.
Phase III Design and Efficacy Results
Patients in the trials were randomised 1:1 to inclisiran or placebo. Following initial doses on the first day and in the third month, maintenance doses were administered every 6 months.
Inclisiran produced a consistent LDL cholesterol reduction of up to 52% compared with placebo at month 17.
Safety profile: An inclisiran toxicity analysis
Inclisiran is generally well tolerated. In phase III trials, the frequency of adverse events was similar to that in the placebo group. The most notable difference was mild injection-site reactions.
| Side Effect (Adverse Event) | Inclisiran Group (%) | Placebo Group (%) | Severity / Clinical Note |
|---|---|---|---|
| Injection-Site Reaction | 8.2% | 1.8% | Mild/Moderate Pain, redness or rash. |
| Arthralgia (Joint Pain) | 5.0% | 4.0% | Clinically similar. |
| Urinary Tract Infection | 4.4% | 3.6% | Clinically similar. |
| Diarrhoea (Loose Stools) | 3.9% | 3.5% | Clinically similar. |
| Bronchitis / Upper Respiratory Tract Infection | 4.3% | 3.9% | Often seasonal. |
| Pain in the Extremities | 3.3% | 3.2% | No clinical difference. |
| Dyspnoea (Shortness of Breath) | 2.6% | 2.4% | No clinical difference. |
*Data are taken from pooled ORION phase III analyses. No treatment-related deaths were reported in the inclisiran arm.
The Situation in Turkey: LYPTİMZİA® 284 mg
The inclisiran molecule is licensed in Turkey under the brand name LYPTİMZİA . The drug contains 284 mg inclisiran sodium in a 1.5 ml ready-to-use syringe. It is administered exclusively by **subcutaneous (under-the-skin) injection**; there is no oral (by-mouth) formulation.
Posology and frequency of administration
• Start: First dose (SC Injection)
• Month 3: Second dose (Loading)
• Maintenance: Then a single injection every 6 months.
This infrequent dosing schedule maximises adherence by ending the need to check a medicine box every day.
March 2026 price and availability analysis
These high-technology treatments also bring the cost burden we call “financial toxicity”. Current market data for the US and Turkey are presented below:
| Country / Status | Product and Dose | Estimated Price |
|---|---|---|
| US (List Price) | Leqvio (284 mg) - 1 Syringe | $3,250 - $3,600 |
| Turkey (Official Sales) | LYPTİMZİA (284 mg) - 1 Syringe | ~91700 TL |
Note: The Turkish price is the official retail price determined under the pharmaceutical pricing decree. The drug is imported from abroad in its original form.
DROZDOGAN Academy Commentary
The mindset of “personalised restoration” that we pursue in modern oncology now also beats at the heart of cardiology. Instead of loading the body with medication every day, inclisiran creates a permanent protective shield through a precise intervention performed only twice a year.
A twice-yearly dosing regimen does not merely lower cholesterol; it also frees the patient from the psychology of “being ill”. Healing means hearing the cell’s voice and bringing that voice into balance with the right notes (RNA technology). The medicine of the future is the art of offering more life with fewer doses.
Scientific references and data sources
- 1. Ray KK, et al. Two doses a year of inclisiran to lower LDL cholesterol. NEJM 2020;382:1507-1519.
- 2. TİTCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu) LYPTİMZİA® Kısa Ürün Bilgisi (KÜB) ve Fiyat Listesi (Mart 2026).
- 3. ORION-9, -10, -11 Phase III Clinical Trial Summary Data. JAMA Cardiology 2021.
- 4. FDA Approval Label Update: Leqvio (inclisiran) first-line use. July 31, 2025.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.